Prior work from our lab has demonstrated that treatment of human prostate cancer cell lines with epigenetic modifying agents (EMAs) can lead to expression of other SSX family members, including SSX3, SSX5, and SSX8 [14]. The gene discussed is SSX5; the disease is prostate carcinoma.